![The Readout Loud show](https://d3dthqtvwic6y7.cloudfront.net/podcast-covers/000/082/057/small/the-readout-loud.jpg)
Summary: What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news? We're devoting this entire episode to Biogen's stunning announcement that aducanumab, its once-discarded treatment for Alzheimer's disease, is getting a second life.